Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone844-445-5704
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.46 million
Profitability
Miscellaneous
Employees90
Next Earnings Date8/12/2019 (Estimated)
OptionableNot Optionable
Xeris Pharmaceuticals (NASDAQ:XERS) Frequently Asked Questions
What is Xeris Pharmaceuticals' stock symbol?
Xeris Pharmaceuticals trades on the NASDAQ under the ticker symbol "XERS."
How were Xeris Pharmaceuticals' earnings last quarter?
Xeris Pharmaceuticals Inc (NASDAQ:XERS) released its quarterly earnings results on Thursday, May, 9th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.76) by $0.31. The company had revenue of $0.25 million for the quarter, compared to analyst estimates of $0.30 million. Xeris Pharmaceuticals had a negative return on equity of 75.93% and a negative net margin of 2,997.96%. View Xeris Pharmaceuticals' Earnings History.
When is Xeris Pharmaceuticals' next earnings date?
What price target have analysts set for XERS?
4 Wall Street analysts have issued 1 year price targets for Xeris Pharmaceuticals' stock. Their forecasts range from $23.00 to $27.00. On average, they anticipate Xeris Pharmaceuticals' stock price to reach $24.50 in the next year. This suggests a possible upside of 126.4% from the stock's current price. View Analyst Price Targets for Xeris Pharmaceuticals.
What is the consensus analysts' recommendation for Xeris Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xeris Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xeris Pharmaceuticals.
What are Wall Street analysts saying about Xeris Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xeris Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Xeris Pharmaceuticals, Inc. produces peptides, proteins, antibodies, molecules, auto-injectors, multi-dose pens and infusion pumps to treat endocrine and metabolic diseases. The company's proprietary formulation technologies consist of XeriSol (TM) and XeriJect(TM). Xeris Pharmaceuticals, Inc. is based in Chicago, United States. " (1/12/2019)
- 2. Mizuho analysts commented, "We continue to see Xeris’ glucagon rescue pen as a superior option for the treatment of severe hypoglycemia from a product profile perspective, as we believe there is a higher probability of successfully delivering the full dose to the patient in an emergency situation. Management believes the product could do much better than a 50% market share." (12/4/2018)
Has Xeris Pharmaceuticals been receiving favorable news coverage?
News headlines about XERS stock have been trending somewhat positive recently, InfoTrie reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Xeris Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Xeris Pharmaceuticals.
Are investors shorting Xeris Pharmaceuticals?
Xeris Pharmaceuticals saw a increase in short interest in the month of May. As of May 31st, there was short interest totalling 1,560,900 shares, an increase of 18.2% from the April 30th total of 1,320,200 shares. Based on an average daily trading volume, of 227,500 shares, the short-interest ratio is presently 6.9 days. Approximately 7.0% of the shares of the stock are sold short. View Xeris Pharmaceuticals' Current Options Chain.
Who are some of Xeris Pharmaceuticals' key competitors?
Some companies that are related to Xeris Pharmaceuticals include Ra Pharmaceuticals (RARX), Radius Health (RDUS), Dicerna Pharmaceuticals (DRNA), G1 Therapeutics (GTHX), Clementia Pharmaceuticals (CMTA), Eidos Therapeutics (EIDX), OrganiGram (OGI), Amphastar Pharmaceuticals (AMPH), Alder Biopharmaceuticals (ALDR), Theravance Biopharma (TBPH), ANI Pharmaceuticals (ANIP), Spectrum Pharmaceuticals (SPPI), ZIOPHARM Oncology (ZIOP), Deciphera Pharmaceuticals (DCPH) and Wave Life Sciences (WVE).
What other stocks do shareholders of Xeris Pharmaceuticals own?
Who are Xeris Pharmaceuticals' key executives?
Xeris Pharmaceuticals' management team includes the folowing people:
- Mr. Paul R. Edick, Pres, CEO & Chairman (Age 63)
- Mr. Barry M. Deutsch, Chief Financial Officer (Age 54)
- Mr. John P. Shannon, Exec. VP & COO (Age 57)
- Dr. Steven J. Prestrelski, Co-Founder & Chief Scientific Officer (Age 55)
- Ms. Allison Wey, Sr. VP of Investor Relations & Corp. Communications
When did Xeris Pharmaceuticals IPO?
(XERS) raised $75 million in an initial public offering on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Mizuho Securities was co-manager.
Who are Xeris Pharmaceuticals' major shareholders?
Xeris Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (11.14%), FMR LLC (11.00%), Marshall Wace LLP (0.09%), Rhumbline Advisers (0.09%), Marshall Wace North America L.P. (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Xeris Pharmaceuticals stock include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick, Redmile Group, Llc and Steven Prestrelski. View Institutional Ownership Trends for Xeris Pharmaceuticals.
Which institutional investors are buying Xeris Pharmaceuticals stock?
XERS stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Redmile Group LLC, Marshall Wace LLP, Rhumbline Advisers, Marshall Wace North America L.P. and BNP Paribas Arbitrage SA. Company insiders that have bought Xeris Pharmaceuticals stock in the last two years include Beth Hecht, James E Flynn, Palmetto Partners, Ltd, Paul R Edick and Redmile Group, Llc. View Insider Buying and Selling for Xeris Pharmaceuticals.
How do I buy shares of Xeris Pharmaceuticals?
Shares of XERS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xeris Pharmaceuticals' stock price today?
One share of XERS stock can currently be purchased for approximately $10.82.
How big of a company is Xeris Pharmaceuticals?
Xeris Pharmaceuticals has a market capitalization of $291.49 million and generates $2.46 million in revenue each year. The company earns $-60,080,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Xeris Pharmaceuticals employs 90 workers across the globe.View Additional Information About Xeris Pharmaceuticals.
What is Xeris Pharmaceuticals' official website?
How can I contact Xeris Pharmaceuticals?
Xeris Pharmaceuticals' mailing address is 180 N. LaSalle Street Suite 1810, Chicago IL, 60601. The company can be reached via phone at 844-445-5704 or via email at [email protected]
MarketBeat Community Rating for Xeris Pharmaceuticals (NASDAQ XERS)
MarketBeat's community ratings are surveys of what our community members think about Xeris Pharmaceuticals and other stocks. Vote "Outperform" if you believe XERS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XERS will underperform the S&P 500 over the long term. You may vote once every thirty days.
